Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Taneja

Showing results (341-350 of 845) with videos related to

Pageof 85
Sort By:
The Urologic Clinics of North America|November 27, 2012
Urologic Clinics of North America. Multidisciplinary management of urinary stone disease. ForewordSamir S Taneja
The Journal of Urology|December 23, 2018
Re: Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerSamir S Taneja
The Journal of Urology|November 12, 2019
Re: Oncological and Quality-of-Life Outcomes following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-Monitored Prospective CohortSamir S Taneja
The Journal of Urology|December 13, 2019
Re: Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a De Novo Low AR-Active Subclass in Treatment Naïve Primary Prostate CancerSamir S Taneja
European Urology|June 20, 2024
Reducing or Increasing Overtreatment? How Do We Measure the Impact of Magnetic Resonance Imaging-targeted Biopsy on Prostate Cancer Mortality?Samir S Taneja
The Journal of Urology|November 11, 2018
Re: Comparison between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer with Adverse Pathological FeaturesSamir S Taneja
The Journal of Urology|November 11, 2018
Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health SystemSamir S Taneja
The Journal of Urology|October 27, 2018
Re: Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and EnzalutamideSamir S Taneja
The Journal of Urology|October 27, 2018
Re: Effects of Pathological Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in Men with Clinical Low-Risk Prostate CancerSamir S Taneja
The Journal of Urology|October 19, 2016
Re: Hypofractionated Radiotherapy versus Conventionally Fractionated Radiotherapy for Patients with Intermediate-Risk Localised Prostate Cancer: 2-Year Patient-Reported Outcomes of the Randomised, Non-Inferiority, Phase 3 CHHiP TrialSamir S Taneja
Pageof 85

Showing results (341-350 of 845) with videos related to

Sort By:
Pageof 85
The Urologic Clinics of North America|November 27, 2012
Urologic Clinics of North America. Multidisciplinary management of urinary stone disease. ForewordSamir S Taneja
The Journal of Urology|December 23, 2018
Re: Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate CancerSamir S Taneja
The Journal of Urology|November 12, 2019
Re: Oncological and Quality-of-Life Outcomes following Focal Irreversible Electroporation as Primary Treatment for Localised Prostate Cancer: A Biopsy-Monitored Prospective CohortSamir S Taneja
The Journal of Urology|December 13, 2019
Re: Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a De Novo Low AR-Active Subclass in Treatment Naïve Primary Prostate CancerSamir S Taneja
European Urology|June 20, 2024
Reducing or Increasing Overtreatment? How Do We Measure the Impact of Magnetic Resonance Imaging-targeted Biopsy on Prostate Cancer Mortality?Samir S Taneja
The Journal of Urology|November 11, 2018
Re: Comparison between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer with Adverse Pathological FeaturesSamir S Taneja
The Journal of Urology|November 11, 2018
Re: Validation of the 2015 Prostate Cancer Grade Groups for Predicting Long-Term Oncologic Outcomes in a Shared Equal-Access Health SystemSamir S Taneja
The Journal of Urology|October 27, 2018
Re: Germline DNA-Repair Gene Mutations and Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Abiraterone and EnzalutamideSamir S Taneja
The Journal of Urology|October 27, 2018
Re: Effects of Pathological Upstaging or Upgrading on Metastasis and Cancer-Specific Mortality in Men with Clinical Low-Risk Prostate CancerSamir S Taneja
The Journal of Urology|October 19, 2016
Re: Hypofractionated Radiotherapy versus Conventionally Fractionated Radiotherapy for Patients with Intermediate-Risk Localised Prostate Cancer: 2-Year Patient-Reported Outcomes of the Randomised, Non-Inferiority, Phase 3 CHHiP TrialSamir S Taneja
Pageof 85